Compare Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Haleon plc American Depositary Shares (Each representing two Ordinary Shares) vs Relay Therapeutics Inc. Common Stock — how do they compare? Haleon plc American Depositary Shares (Each representing two Ordinary Shares) trades at $9.3 (market cap $40.01B), while Relay Therapeutics Inc. Common Stock trades at $17.62 (market cap $3.82B). The key difference: Haleon plc American Depositary Shares (Each representing two Ordinary Shares) is far larger — about 10.5× Relay Therapeutics Inc. Common Stock's market cap, and Haleon plc American Depositary Shares (Each representing two Ordinary Shares) pays a 2.14% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Haleon plc American Depositary Shares (Each representing two Ordinary Shares) for 0 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| HLN | RLAY | |
|---|---|---|
Market Cap | $40.01B | $3.82B |
Volume | 19,985,935 | 4,332,079 |
Sector | Health | Health |
52-Week High | $11.27 | $20.75 |
52-Week Low | $8.70 | $6.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $49.79B | $2.93B |
Dividend Yield | 2.14% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
Haleon is a consumer healthcare company offering over-the-counter medicines, oral health products, vitamins, and wellness brands.
Read more on HLN →About Relay Therapeutics Inc. Common Stock
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →
